nature.com· Vidyalakshmi Chandramohan·· 13 hours agoPickScore48
EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial
EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial
In brief
A phase 1 trial of D2C7-ATC, an antibody-toxin conjugate targeting EGFR and EGFRvIII, in patients with recurrent malignant glioma showed encouraging safety and efficacy signals. Translational analyses of patient samples indicated intratumoral and systemic immune activation. The results support the conjugate as a candidate strategy for recurrent malignant glioma.
Why it matters
Phase 1 data on an EGFR/EGFRvIII-targeted antibody-toxin conjugate in recurrent malignant glioma with immune activation evidence.
Source: nature.com · nature.com